Lung Cancer Clinical Trials in Cleveland

Showing 401-420 of 660 trials

Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00970684

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as docetaxel and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with docetaxel and gemcitabine hydrochloride may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving bevacizumab together with docetaxel and gemcitabine hydrochloride works in treating patients with stage IIIB, stage IV, or recurrent non-small cell lung cancer.

Lung Cancer

Nathan Pennell, MD, PhD13 participantsStarted Sep 2009

Cleveland, Ohio, United States • Cleveland, Ohio, United States • Cleveland, Ohio, United States +1 more locations

UNKNOWNPhase 1/290 miles

PEN-866 in Patients With Advanced Solid Malignancies

NCT03221400

Protocol PEN-866-001 is an open-label, multi-center, first-in-human Phase 1/2a study evaluating PEN-866 in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.

CarcinomaEndometrial AdenocarcinomaNeoplasms+16 more

Tarveda Therapeutics340 participantsStarted Aug 2017

Springdale, Arkansas, United States • Denver, Colorado, United States • Fort Myers, Florida, United States +13 more locations

Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

PEN-866 in Patients With Advanced Solid Malignancies

Lung Cancer Trials in Other Cities

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC

Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

Safety Study of MGA271 in Refractory Cancer

Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin

A Study of LY3023414 in Participants With Advanced Cancer

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Other Conditions in Cleveland